AXAxinet
Menu
Finance

Live market screen

Commercial Space Company Risk / Opportunity Ranking

Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.

Updated June 27, 2026

Companies analyzed
438
Ranked rows
876
Evidence links
356
Rows per page
20

Opportunity view

Showing rows 261-280 of 438; 20 rows per page.

Sorted by raw opportunity score
RankCompanyScoreThesis / Evidence
261
Agnikul Cosmos
lowweak
Opp 1
Risk 1

Thesis: Insufficient admissible reviewed sources evidence to form a positive thesis within the selected recent evidence window. Membership rationale says the company is a rocket startup raising funding and planning an orbital debut, but no surviving article/evidence are provided for direct support.

Why now: Why now is unsupported because the reviewed sources show zero evidence after recent evidence filtering despite many articles considered; recency-specific business state cannot be established from the provided evidence.

Caveats: Coverage debug shows zero evidence after recent evidence filtering. Membership rationale cannot substitute for cited directional evidence under the output rules. Absence of evidence is not positive or negative proof.

262
Airbus SE
lowweak
Opp 1
Risk 1

Thesis: The reviewed sources gives only weak context that Airbus was listed in a satellite-servicing landscape, which is insufficient on its own to support a strong positive thesis for a 1 year+ horizon.

Why now: There is no within the recent evidence window evidence available for Airbus; the only cited article is older context published March 4, 2025, outside the 90-day cutoff noted by the reviewed sources, so recency support is weak.

Caveats: Coverage after recent evidence window is effectively empty: articles after recent evidence window is 0. The available Airbus article is contextual and outside the 90-day recent evidence window. Cohort membership does not establish attractiveness.

263
Alta Ares
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable because the retained reviewed sources contain no direct positive evidence after recent evidence window.

Why now: Why now is weak: the reviewed sources show no retained evidence after recent evidence window, and the membership rationale says Alta Ares appears only in a broad funding roundup without enough company-specific detail.

Caveats: Phase-2 membership rationale references: but no article summary or direct retained evidence is available here for factual use. The reviewed sources itself says company-specific detail is insufficient.

264
Altamira Technologies Corporation
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable because the reviewed sources does not provide direct positive evidence or article summaries for Altamira in the scoring section.

Why now: The phase2 rationale notes only that Parsons acquired Altamira and references defense/national security themes, but no citable evidence are provided here. Coverage data shows zero articles after recent evidence window and zero evidence available.

Caveats: Ownership/acquisition context alone is not enough without direct evidence detail. No dated catalyst evidence is surfaced in the reviewed sources.

265
Amazon.com Inc.
lowweak
Opp 1
Risk 1

Thesis: The membership rationale references satellite and direct-to-device ambitions, but the reviewed sources contain no within the recent evidence window evidence or representative article summaries to support a current space-related opportunity thesis here.

Why now: No current catalyst can be established from the available evidence because post-recent evidence window evidence are absent.

Caveats: Extremely large mention universe is not conviction. No usable evidence were available after recent evidence window.

266
AnduraX
lowweak
Opp 1
Risk 1

Thesis: The reviewed sources' membership rationale says AnduraX is developing a reusable spaceplane and has VC backing, but no retained within the recent evidence window article evidence is available here to support an opportunity thesis.

Why now: There is no retained article or evidence row after the 90-day recent evidence window, so the reviewed sources does not establish a current catalyst or updated business state.

Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale references article IDs, and: but no or retained summaries are provided here. Scores remain low because positive or negative direction cannot be grounded with citable retained evidence.

267
Angkasa-X Holdings Corp.
lowweak
Opp 1
Risk 1

Thesis: No retained within the recent evidence window direct positive evidence is provided in the reviewed sources, so there is not enough support for a positive 1 year+ thesis.

Why now: There is no usable within the recent evidence window article evidence available for ranking; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency-sensitive judgment is not possible from these reviewed sources alone.

Caveats: Reviewed evidence notes one considered article for membership support but zero article IDs after recent evidence window and zero available evidence after recent evidence window, so ranking is constrained by evidence absence rather than business absence. Membership rationale references article: but the reviewed sources does not provide the article or a retained within the recent evidence window evidence row for ranking use.

268
Applied Aerospace & Defense Inc.
lowweak
Opp 1
Risk 1

Thesis: There is insufficient company-specific positive evidence in the reviewed sources to support an opportunity thesis. The only cited context is that the company was referenced as competition in a space-sector article and that the reviewed sources notes a $650M IPO, but no direct business traction, contract, product, or financial evidence within the recent evidence window is available (: unavailable in reviewed sources).

Why now: Why now is weak because the reviewed sources show zero evidence available after the 90-day recent evidence window cutoff date of March 29, 2026, so recency-based catalysts cannot be established from these reviewed sources.

Caveats: No current evidence is provided for cited Evidence rows available after recent evidence window: 0. Mention as competition or IPO context is weaker than direct company event evidence.

269
Argotec
lowweak
Opp 1
Risk 2

Thesis: There is not enough kept recent evidence window evidence in these reviewed sources to form a positive 1 year+ thesis beyond weak historical cohort relevance.

Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, and the only cited support is an older membership rationale referring to 7 Hawk microsatellites for Italy's IRIDE constellation aboard a SpaceX launch from article: but no article or dated evidence row is provided in the reviewed sources for ranking use.

Caveats: No article is provided for the membership support article: so it cannot be cited as a factual ranked-evidence item under the the evidence standard. Coverage debug shows zero evidence after recent evidence window. Private/public status is not used as a filter and is unclear from these reviewed sources.

270
ArianeGroup
lowweak
Opp 1
Risk 1

Thesis: ArianeGroup appears relevant to launch services in the phase2 rationale, but the reviewed sources provide no direct positive evidence or citable representative summaries for a ranked positive thesis.

Why now: The phase2 rationale references Ariane 6/Arianespace launch context for Amazon Kuiper, but relation/context evidence cannot be used as counterparty propagation and no direct evidence is exposed in the scoring fields. Coverage data shows zero articles after recent evidence window and zero evidence available.

Caveats: Do not use context-only relation logic as direct thesis proof. No direct company-specific event evidence is included here.

271
Arxis, Inc.
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supported within the retained 90-day evidence window; the reviewed sources only shows older cohort-membership context identifying Arxis as a small satellite manufacturer from article, but no in-window direct positive event or fact is available.

Why now: Why now is unclear because coverage data shows 0 articles after recent evidence window and 0 evidence after recent evidence window, so there is no retained recent catalyst evidence in the reviewed sources.

Caveats: Reviewed evidence cites membership support from, but no representative article is provided, so the underlying claim cannot be restated as direct scored evidence with. Coverage after recent evidence window is empty, limiting conviction.

272
Arxis Inc.
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable from the retained reviewed sources evidence because no direct positive evidence survived the 90-day recent evidence window.

Why now: Why now is weak: the reviewed sources show zero evidence after recent evidence window for Arxis Inc., so there is no current catalyst or current business-state proof in the retained record.

Caveats: Coverage after recent evidence window is empty for this company. Phase-2 membership rationale references support references including: but no article summary or quoted evidence is included in the retained reviewed sources, so it cannot be used for factual claims here.

273
Aselsan
lowweak
Opp 1
Risk 1

Thesis: No retained in-recent evidence window evidence supports a current positive thesis, even though the membership rationale notes LUNA-2 nanosatellite activity.

Why now: The reviewed sources retained zero evidence after the 90-day cutoff, so there is no current catalyst evidence for the 1 year+ ranking despite article-based membership context.

Caveats: Membership rationale cites article, but no article summary or retained evidence row is available here. 24 articles were considered, but none remained after recent evidence filtering.

274
Astranis Space Technologies
lowweak
Opp 1
Risk 1

Thesis: Reviewed evidence rationale references selection under the U.S. Space Force Andromeda program, which could be strategically positive, but no retained evidence are present here to support ranking it higher.

Why now: No retained article or facts remain in the reviewed sources after recent evidence window, so timing and durability cannot be judged from local evidence.

Caveats: Opportunity view depends on uncited membership rationale rather than retained evidence. No recency-confirmed direct evidence in reviewed sources.

275
Astro Digital
lowweak
Opp 1
Risk 1

Thesis: No strong positive thesis is supported. The reviewed sources only says Astro Digital was named as one of Star Catcher's signed power purchase agreement counterparties, implying operation of satellites or space assets, but this is counterparty context from a single article and not sufficient as direct positive evidence (: no provided in reviewed sources).

Why now: No supported current catalyst. The reviewed sources explicitly warns this is counterparty context only, and coverage debug shows no retained evidence after recent evidence window.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Counterparty context should not be treated as strong propagation evidence. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

276
Astrobiome Space
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable from retained evidence in these reviewed sources because no direct positive rows survive the recent evidence window.

Why now: There is no retained evidence showing a current contract milestone, financing event, or product progress inside the recent evidence window.

Caveats: Phase-2 rationale says Astrobiome Space contracted Redwire for a commercial space greenhouse/ISS agriculture mission and cites: and: but no or summaries are available here. Coverage debug shows 6 articles considered and 0 after recent evidence window. Relationship context should not be propagated as stronger evidence without direct retained event/facts.

277
Axiom Space
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable from within the recent evidence window evidence in these reviewed sources. The only cited article is an older external article noting Axiom previously received a NASA commercial space station contract, but it is dated September 2, 2025 and falls outside the reviewed sources' 90-day recent evidence window, so it cannot support a current opportunity call.

Why now: There is no within the recent evidence window catalyst in the available evidence. The only cited context is an older article with September 2, 2025, outside the 90-day evidence window

Caveats: Coverage after recent evidence window is effectively empty: evidence after recent evidence window is 0. Older supporting context exists but was excluded by the 90-day recent evidence window. No direct positive or negative evidence is available.

278
Axiom Space Inc.
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable because the reviewed sources provide no direct positive evidence or citable representative article summaries in the final evidence fields.

Why now: The phase2 rationale says Axiom was mentioned in connection with a lunar suit presentation and an orbital data center feature, but those article details are not surfaced in citable evidence here. Coverage data shows zero articles after recent evidence window and zero available evidence, so there is no current catalyst basis in the reviewed sources.

Caveats: Phase2 rationale is weaker than direct event/fact evidence. No dated current-state evidence is available in the scoring fields.

279
BAE Systems plc
lowweak
Opp 1
Risk 1

Thesis: There may be a space-related opportunity because the membership rationale says BAE Systems was selected by the U.S. Space Force for the Andromeda program, but the reviewed sources does not load the underlying within the recent evidence window evidence or article summaries needed to support a directional thesis.

Why now: Why-now is weak because the reviewed sources show no reviewed evidence after recent evidence window despite many articles considered, leaving no admissible dated evidence in the current output batch.

Caveats: Membership rationale references, and, but no article summaries or evidence are provided here. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Broad-company membership in a cohort is not itself a directional opportunity thesis.

280
Baykar
lowweak
Opp 1
Risk 1

Thesis: No positive thesis is supportable because the retained reviewed sources provide no direct positive evidence for Baykar within the recent evidence window.

Why now: Why now is weak: there are no retained evidence after recent evidence window, and the reviewed sources' membership rationale is based only on weak indirect article context.

Caveats: Phase-2 membership rationale cites and says Fergani Space was described as 'Baykar affiliated,' but no article summary or quote is available in the retained reviewed sources for factual use here. The reviewed sources itself characterizes the evidence as weak, indirect article context.

Risk view

Showing rows 361-380 of 438; 20 rows per page.

Sorted by raw risk score
RankCompanyScoreThesis / Evidence
361
Safran
lowweak
Opp 1
Risk 1

Thesis: The reviewed sources also does not provide direct adverse evidence within the available 90-day evidence set, so there is no basis for a material risk thesis beyond uncertainty from missing evidence coverage.

Why now: There is no current catalyst in the reviewed sources. Coverage debug shows 270 article IDs considered but 0 article IDs after recent evidence window and 0 evidence available after dedupe, so recency-based thesis formation is not supported.

Caveats: Membership rationale references article IDs 2026-04, and, but no are provided in the reviewed sources, so they cannot be cited as factual scoring evidence under the the evidence standard. Evidence recent evidence review shows 0 kept rows after the 90-day cutoff.

362
Sanyark Space Technologies
lowweak
Opp 2
Risk 1

Thesis: No direct negative evidence is available. Risk is mainly that accelerator inclusion alone is too weak to support a durable company thesis, especially over a 1 year+ horizon without proof of funding, contracts, or product milestones (: not provided in reviewed sources).

Why now: There is no supported timing edge because the reviewed sources have zero direct evidence after recent evidence window and no dated article details beyond the structure.

Caveats: Accelerator participation is weaker than company-specific funding or contract evidence. The article appears to describe a cohort rather than a company-specific event. No, quote, or direct event row is available.

363
SatLeo Labs
lowweak
Opp 1
Risk 1

Thesis: No material adverse evidence is available in the reviewed sources.

Why now: No retained within the recent evidence window evidence are provided, so there is no reviewed sources-supported why-now beyond cohort inclusion rationale.

Caveats: Only membership rationale is available; no citeable retained evidence. Small-company universe but zero available evidence after recent evidence window.

364
SatVu
lowweak
Opp 2
Risk 1

Thesis: No retained within the recent evidence window direct negative evidence is provided in the reviewed sources.

Why now: There is no usable within the recent evidence window evidence after filtering; the only cited article is older than the March 29, 2026 cutoff and therefore not timely support for a 1 year+ ranking under these reviewed sources' evidence policy.

Caveats: The reviewed sources report zero kept rows after recent evidence window for SatVu. Older funding evidence exists but was dropped by policy, so recency is insufficient for a stronger score.

365
Scale AI
lowweak
Opp 2
Risk 1

Thesis: The risk case is limited by lack of direct adverse evidence in the reviewed sources; the primary risk is evidentiary rather than operational because no retained post-recent evidence window event details, award sizing to the company, or execution milestones are available.

Why now: Why now is muted because the reviewed sources references support article in membership rationale, but no, article summary, or retained evidence after the 90-day filter are available to confirm timing or scope.

Caveats: Despite 273 articles considered, coverage data shows articles after recent evidence window 0 and evidence after recent evidence window 0. The contract claim is only present in membership rationale citing article without a in the served reviewed sources. Opportunity score is kept low because the the evidence standard require direct positive evidence, not just membership inclusion.

366
Schaeffler AG
lowweak
Opp 2
Risk 1

Thesis: No material negative evidence is available within the reviewed sources recent evidence window. Risk remains low on evidence, not necessarily in reality.

Why now: No surviving 90-day evidence are available despite 94 articles considered. The only support is the membership rationale reference to: but the reviewed sources provide no and no retained evidence.

Caveats: Membership rationale is not sufficient directional proof. No direct positive or negative evidence survived the recent evidence window. Industrial-partner status versus core space-company status is unclear from the reviewed sources.

367
SciTec
lowweak
Opp 1
Risk 1

Thesis: No material negative evidence is retained, leaving no evidence-based risk case.

Why now: No current catalyst is established because the reviewed sources retains no company-specific evidence after the 90-day filter.

Caveats: Phase-2 rationale references, but no or retained summary is available in the reviewed sources. Support level is provisional single-article context. No direct company-specific positive or negative evidence remain after recent evidence window.

368
SEALCOIN AG
lowweak
Opp 2
Risk 1

Thesis: No material adverse evidence is retained.

Why now: The membership rationale says SEALCOIN secured strategic investment for space-based blockchain infrastructure leveraging a satellite constellation, tied to article: but no or retained evidence are present after recent evidence window.

Caveats: Only rationale-level description is available; no retained direct evidence row with is supplied. The business category fit is ambiguous in the reviewed sources itself.

369
SEALSQ Corp
lowweak
Opp 1
Risk 1

Thesis: The reviewed sources also provides no retained material adverse evidence, leaving risk unsupported beyond baseline uncertainty.

Why now: There is no usable current evidence because articles after recent evidence window = 0 and evidence after recent evidence window = 0 following the March 29, 2026 cutoff.

Caveats: No surviving recent evidence window-qualified evidence. Space relevance in reviewed sources rationale does not establish direction.

370
SES S.A.
lowweak
Opp 1
Risk 1

Thesis: No material adverse evidence is available for SES. Risk score remains low because of lack of evidence, not because risk has been disproven.

Why now: Why-now is weak because no reviewed evidence are available after recent evidence window, so recency and catalysts cannot be assessed from the reviewed sources.

Caveats: Membership rationale references and, but no corresponding available article summaries or evidence are provided. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Cohort membership does not establish opportunity.

371
Sidus Space Inc.
lowweak
Opp 1
Risk 1

Thesis: No within the recent evidence window direct negative evidence was available, so the reviewed sources does not support a material risk thesis.

Why now: There is no retained dated company evidence after the 90-day recent evidence window; timing support for a 1 year+ thesis is absent in the reviewed sources.

Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. The membership rationale mentions article IDs, and, but no or retained evidence content are provided in these reviewed sources.

372
SkyFi
lowweak
Opp 1
Risk 1

Thesis: No direct negative evidence is available, so there is no supportable downside thesis from these reviewed sources alone.

Why now: Membership rationale says SkyFi was mentioned as a commercial access partner for Vantor's satellite imagery constellation in article, but this is only contextual and no or direct evidence are provided.

Caveats: Partner context is weaker than direct company evidence. No evidence available after recent evidence filtering. Referenced has no in the reviewed sources.

373
Skyfora
lowweak
Opp 1
Risk 1

Thesis: There is no retained direct adverse evidence in the reviewed sources after recent evidence window, so any risk thesis would be speculative rather than evidence-based.

Why now: No within the recent evidence window company-specific catalyst is provided. The reviewed sources reports zero reviewed evidence after the 90-day cutoff for Skyfora, so recency is insufficiently grounded.

Caveats: Phase-2 rationale references a €6.5M raise tied to: but no representative article, or retained evidence row is provided in these reviewed sources, so it cannot be used as direct scored evidence. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership review status is not directional proof.

374
Solestial Inc.
lowweak
Opp 1
Risk 1

Thesis: No material adverse thesis is supportable from these reviewed sources because no retained direct negative evidence is provided inside the recent evidence window.

Why now: No current catalyst can be established from the reviewed sources; the company has zero evidence after recent evidence window.

Caveats: Phase-2 rationale says York Space Systems acquired Solestial and cites: but no article summary or is provided here, so it cannot be used as cited factual support. Coverage debug shows 4 articles considered and 0 article IDs after recent evidence window. Absence of evidence is not positive or negative proof.

375
Solstar Space Company
lowweak
Opp 1
Risk 1

Thesis: No material negative evidence is available, so there is no supported adverse thesis from the evidence provided.

Why now: The reviewed sources contain no reviewed evidence after recent evidence window for this company, preventing a recency-based 1 year+ ranking judgment beyond watchlist status.

Caveats: Membership rationale references article, but no direct summary or evidence row is available here for citation. Coverage debug shows zero available evidence after recent evidence window. Private-company status is not itself positive or negative.

376
Space Mission Systems
lowweak
Opp 2
Risk 1

Thesis: No direct negative evidence is available. The main risk is identity ambiguity and insufficient grounding rather than a demonstrated adverse development.

Why now: The only potential 'why now' is contract-related context in the membership rationale, but it is not sufficiently tied to this entity and no dated scoring evidence with is available.

Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Entity identification is unclear in the reviewed sources.

377
Space Systems/Loral, LLC (SSL)
lowweak
Opp 1
Risk 1

Thesis: No direct adverse evidence is available in the reviewed sources, so risk stays low purely due to missing evidence rather than demonstrated resilience.

Why now: No current catalyst can be established because coverage debug shows 0 article IDs after recent evidence window and 0 evidence after recent evidence window. The rationale cites: without a in these reviewed sources.

Caveats: Only industry-report context is referenced in membership rationale. No direct event/fact evidence survived the recent evidence window.

378
Space42
lowweak
Opp 1
Risk 1

Thesis: No retained adverse evidence is provided, so there is no material evidence-based risk thesis in these reviewed sources.

Why now: Why now is weak because coverage data shows no articles after recent evidence window and no evidence after recent evidence window.

Caveats: Membership rationale references article IDs but no are provided, so they cannot be used as cited factual support here. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0.

379
Spaceflux
lowweak
Opp 3
Risk 1

Thesis: No material negative evidence is available. The main risk is that the cited funding amount may be too small to be strategically meaningful, but the reviewed sources does not provide direct adverse evidence or enough detail to rank this as a strong risk name (: not provided in reviewed sources).

Why now: A follow-on investment could matter over 1 year+ if it extends development in debris tracking, but there is no available dated evidence within the recent evidence window and no direct article summary/ in the reviewed sources.

Caveats: Only article-level rationale is available. Funding size may be modest, but reviewed sources does not provide enough context to judge materiality precisely. No representative article or quote available.

380
SpaceLocker
lowweak
Opp 1
Risk 1

Thesis: There is not enough retained evidence in the recent evidence window to support a material risk thesis.

Why now: No article-level or event-level evidence were retained after the March 29, 2026 recent evidence window cutoff; recency for the membership rationale is therefore unusable for ranking.

Caveats: Membership rationale references article, but no representative article summary or retained evidence row is included. Single-article universe with zero retained rows limits confidence materially.